IELSG-19 Trial

Trial Name:

Multicenter randomised trial of chlorambucil versus chlorambucil plux rituximab versus rituximab alone in extranodal marginal zone B-Cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma).

Objectives:

The aim of this study is to assess the therapeutic activity and safety of the combination of Chlorambucil and Rituximab in MALT lymphomas and to determine whether the addition of Rituximab to Chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with Chlorambucil alone.

In April 2006, a third arm of treatment was added to compare the antitumor activity and safety of rituximab alone vs chlorambucil alone.

Design:

This is a multicenter randomized phase III trial.

Status:

Completed

Population:

450 patients from 8 countries with Extranodal Marginal Zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue.

Publications:

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study.

Contact Details:

All Trial enquiries should be addressed to [email protected]